---
title: "Profound Medical to Host Investor Call March 13 on First CAPTAIN Trial Outcomes Presented at EAU 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278405946.md"
description: "Profound Medical will present the first clinical outcomes from the CAPTAIN trial comparing TULSA to robotic radical prostatectomy at EAU 2026 on March 13, 2026. Dr. Laurence Klotz will present during the Late-Breaking & High-Impact session at 9:40 a.m. EDT, followed by an investor webinar at 11:30 a.m. EDT to discuss the data and its commercial implications. Management will also hold one-on-one meetings at the ROTH Conference from March 22–24 in Dana Point, with no webcast available for those meetings."
datetime: "2026-03-09T14:03:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278405946.md)
  - [en](https://longbridge.com/en/news/278405946.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278405946.md)
---

# Profound Medical to Host Investor Call March 13 on First CAPTAIN Trial Outcomes Presented at EAU 2026

**Profound Medical to present first CAPTAIN trial clinical outcomes and host an investor webinar on March 13, 2026.**

**Key Highlights:**

-   First clinical outcomes from the Level 1 post-market CAPTAIN trial comparing TULSA to robotic radical prostatectomy will be presented at EAU 2026 on March 13.
-   Presentation by Dr. Laurence Klotz during the Late-Breaking & High-Impact session at 9:40 a.m. EDT; company will issue a summary press release after the presentation.
-   Investor webinar with Dr. Klotz and management to review CAPTAIN data and discuss commercial implications at 11:30 a.m. EDT; advanced registration required.
-   Management will hold one-on-one meetings at the ROTH Conference March 22–24 in Dana Point; no webcast available for those meetings.

Original SEC Filing: Profound Medical Corp. \[ PROF \] - 8-K - Mar. 09, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PROF.US](https://longbridge.com/en/quote/PROF.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)

## Related News & Research

- [PolyPid To Present New Phase 3 SHIELD II Data On D-PLEX100 At ESCMID 2026](https://longbridge.com/en/news/282665678.md)
- [Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year | CSTL Stock News](https://longbridge.com/en/news/282333053.md)
- [MAIA Biotechnology activates first U.S. site for THIO-101 Phase 2 expansion, NIH funds $2.3M](https://longbridge.com/en/news/283011482.md)
- [KALA BIO 10-K: Operating loss $39.16M; Net loss $26.98M](https://longbridge.com/en/news/282893053.md)
- [BUZZ-Precision BioSciences up as hepatitis B gene‑editing trial expands in Europe](https://longbridge.com/en/news/282832865.md)